Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Bakalos

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Resuscitation|May 11, 2011
Advanced life support versus basic life support in the pre-hospital setting: a meta-analysisG Bakalos, M Mamali, C Komninos, et al.
Journal of Clinical Pharmacy and Therapeutics|August 21, 2013
A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosisG M Hadjigeorgiou, C Doxani, M Miligkos, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2018
A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis BH L Y Chan, D Messinger, G V Papatheodoridis, et al.
Alimentary Pharmacology & Therapeutics|March 10, 2018
Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patientsW-L Chuang, J Jia, H L Y Chan, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Resuscitation|May 11, 2011
Advanced life support versus basic life support in the pre-hospital setting: a meta-analysisG Bakalos, M Mamali, C Komninos, et al.
Journal of Clinical Pharmacy and Therapeutics|August 21, 2013
A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosisG M Hadjigeorgiou, C Doxani, M Miligkos, et al.
Alimentary Pharmacology & Therapeutics|June 30, 2018
A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis BH L Y Chan, D Messinger, G V Papatheodoridis, et al.
Alimentary Pharmacology & Therapeutics|March 10, 2018
Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patientsW-L Chuang, J Jia, H L Y Chan, et al.
Pageof 1